Saxenda review: is it worth it?
Saxenda (liraglutide 3.0mg) is a daily injection FDA-approved for chronic weight management.
A proven but now-dated daily GLP-1 option
Saxenda was the first GLP-1 approved purely for weight loss, and the clinical evidence behind it is solid: roughly 8% average body-weight reduction at 56 weeks in the SCALE trial. But it requires a daily injection and, in a head-to-head trial, delivered less than half the weight loss of weekly semaglutide. For most new patients in 2026, it is a second-tier choice unless a daily liraglutide is specifically preferred, better covered, or available more cheaply as a generic. This is general information, not medical advice.
Check PriceFrom $1349/mo
Pros
- ✓Backed by large randomized trials (the SCALE program enrolled thousands of participants) and nearly a decade of real-world safety data since liraglutide's weight-loss approval in 2014
- ✓Clinically meaningful results: about 63% of patients lost 5% or more of body weight in the pivotal SCALE trial
- ✓One of the few weight-management drugs FDA-approved for adolescents aged 12-17, not just adults
- ✓Flexible daily timing, can be injected any time of day with or without food, and the titration can be slowed if side effects appear
- ✓Liraglutide has the longest track record of any GLP-1 used for weight loss, with well-characterized risks, and a lower-cost generic is now available
Cons
- ✕Requires a daily injection, far less convenient than once-weekly competitors Wegovy and Zepbound
- ✕Substantially less effective than newer drugs: STEP 8 showed 6.4% weight loss vs. 15.8% for weekly semaglutide over 68 weeks
- ✕High cash price (often $1,300+ per month) with inconsistent insurance coverage for weight loss and no manufacturer savings card for new patients
- ✕Frequent GI side effects (nausea, vomiting, diarrhea) and a high trial discontinuation rate (about 28% in STEP 8)
- ✕Carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a history of MTC or MEN 2
- ✕Weight is commonly regained after stopping, so it generally requires long-term, ongoing use
How it works
Saxenda's active ingredient is liraglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural gut hormone released after eating. By activating GLP-1 receptors in the brain's appetite centers, it increases feelings of fullness and reduces hunger, which tends to lower how many calories you eat. It also slows stomach emptying, so food stays in the stomach longer. Because liraglutide is relatively short-acting, it must be injected once every day, unlike newer once-weekly GLP-1 drugs.
Active ingredient: Liraglutide
Effectiveness
In the pivotal SCALE Obesity and Prediabetes trial (NEJM, 2015), adults without diabetes lost a mean of 8.0% of body weight on liraglutide 3.0 mg versus 2.6% on placebo at 56 weeks. About 63% of liraglutide patients lost at least 5% of body weight (vs. 27% on placebo) and roughly 33% lost at least 10% (vs. 11% on placebo). However, in the head-to-head STEP 8 trial (JAMA, 2022), once-weekly semaglutide 2.4 mg produced 15.8% mean weight loss versus 6.4% for daily liraglutide 3.0 mg over 68 weeks, more than double the effect. Individual results vary and depend heavily on combining the drug with diet and activity.
Side effects
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, typically mild-to-moderate and worst during the first weeks as the dose is increased. Headache, low blood sugar (especially in people with type 2 diabetes), increased heart rate, and injection-site reactions also occur. Serious but uncommon risks include acute pancreatitis, gallbladder disease (gallstones), and kidney problems from dehydration. Saxenda carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek urgent medical care for severe, persistent abdominal pain, signs of an allergic reaction, or a lump or swelling in the neck.
Cost
Starts at $1349/mo from Novo Nordisk.
As of 2026, Saxenda's cash price without insurance runs roughly $1,300 to $1,650 per month for a 30-day supply (five prefilled pens), varying by pharmacy. Pharmacy discount coupons (e.g., GoodRx) can cut this to around $370-$500. Insurance coverage is inconsistent, often requires prior authorization, and many commercial plans, plus Medicare, exclude weight-loss drugs entirely. Note that Novo Nordisk's $25 Saxenda Savings Card was discontinued for new enrollees in mid-2023, so it is no longer a reliable way to lower cost; uninsured patients with limited income may instead qualify for free medication through the Novo Nordisk Patient Assistance Program. A lower-cost generic liraglutide (from Teva) launched in the US in 2025 at roughly $1,165 per month, which may reduce out-of-pocket costs over time as availability expands.
Is it worth it?
Saxenda genuinely works and has a decade of safety data behind liraglutide, but a head-to-head trial (STEP 8) showed it produced less than half the weight loss of weekly semaglutide. Combined with daily injections and a high cash price, it is hard to recommend as a first choice in 2026 unless cost, coverage, the new generic, or a clinician's judgment points to liraglutide specifically. Discuss newer weekly options with your prescriber before deciding.
Frequently asked questions
How much weight can you lose on Saxenda?
In the pivotal SCALE trial, adults lost an average of about 8% of body weight at 56 weeks versus 2.6% on placebo. Roughly 63% lost at least 5% and about 33% lost at least 10%, when Saxenda was combined with a reduced-calorie diet and exercise. Individual results vary.
Is Saxenda the same as Wegovy or Ozempic?
No. All three are GLP-1 receptor agonists, but Saxenda uses liraglutide injected once daily, while Wegovy and Ozempic use semaglutide injected once weekly. Wegovy is approved for weight loss; Ozempic is approved for type 2 diabetes (though it is sometimes prescribed off-label for weight).
Is Saxenda or Wegovy more effective for weight loss?
Wegovy is more effective. In the head-to-head STEP 8 trial, weekly semaglutide 2.4 mg produced 15.8% average weight loss versus 6.4% for daily Saxenda over 68 weeks, more than double the result.
What are the most common Saxenda side effects?
Nausea is the most common, along with vomiting, diarrhea, constipation, and abdominal pain. These are usually mild-to-moderate and most intense during the first weeks while the dose is being increased. Rare but serious risks include pancreatitis and gallbladder disease.
How much does Saxenda cost per month in 2026?
Without insurance, Saxenda typically costs about $1,300 to $1,650 per month. Discount coupons such as GoodRx can lower it to roughly $370-$500. The $25 Novo Nordisk savings card was discontinued for new enrollees, but a lower-cost generic liraglutide (around $1,165/month) became available in 2025, and a Novo Nordisk patient assistance program may help eligible low-income, uninsured patients.
Do you regain weight after stopping Saxenda?
Yes, weight regain is common after stopping, because Saxenda controls appetite only while you are taking it. Most clinicians treat it as a long-term therapy alongside sustained diet and lifestyle changes rather than a short course.
Who should not take Saxenda?
Avoid Saxenda if you have a personal or family history of medullary thyroid cancer (MTC) or MEN 2, are pregnant, or have had a serious allergic reaction to liraglutide. Use caution if you have a history of pancreatitis or gallbladder disease, and do not combine it with other GLP-1 medicines. Confirm with your doctor.
How is Saxenda injected and on what schedule?
Saxenda is a once-daily injection under the skin of the abdomen, thigh, or upper arm. The dose is increased weekly from 0.6 mg, stepping up to 1.2, 1.8, and 2.4 mg, reaching the 3.0 mg maintenance dose by week 5, which helps reduce nausea.
Sources
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes) — New England Journal of Medicine (2015)
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA (2022)
- SAXENDA (liraglutide) injection, solution - Prescribing Information (Boxed Warning, Dosage & Administration, Indications) — DailyMed / U.S. National Library of Medicine (2024)
- Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection) - First Generic GLP-1 Indicated for Weight Loss — Healio (2025)
- Saxenda Dosage Guide — Drugs.com (2026)